Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00776139 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00776139: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00776139 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00776139, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fasting condition
Interventions
- DRUG Cetirizine Hydrochloride 10 mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00776139
The ClinicalTrials.gov registry entry for NCT00776139 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetirizine Hydrochloride 10 mg tablet is the first listed.
NCT00776139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00776139 about?
NCT00776139 is a clinical study titled "Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions". An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pf...
What is the current status of trial NCT00776139?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2004-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00776139?
The interventions under investigation include: Cetirizine Hydrochloride 10 mg tablet (DRUG).
Who is sponsoring clinical trial NCT00776139?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.